What is it about?
Authors determined that copper depletion using a specific chelating agent reduces proliferation, survival and migration of human colon cancer cells bearing the BRAFV600E mutation acting through inhibition of the mitogen-activated (MAP) kinase pathway.
Featured Image
Photo by Joanna Kosinska on Unsplash
Read the Original
This page is a summary of: Effects of Copper Chelation on BRAFV600E Positive Colon Carcinoma Cells, Cancers, May 2019, MDPI AG,
DOI: 10.3390/cancers11050659.
You can read the full text:
Resources
- Open Access version
Open Access Version
Open Access Pdf
- Other
The Chang Lab Webpage
The Chang Lab Webpage at the University of California, Berkeley, Dept of Chemistry
- Other
The Su Laboratory Publications
The Su Laboratory Publications University of California
- Other
The Heffern Lab Publications
The Heffern Lab Publications
- Press Release
Intestinal Cell News
Intestinal Cell News Volume 5.18 | May 24 2019
- Related Content
Current biomedical use of copper chelation therapy
Int J Mol Sci. 2020; 21(3): 1069. doi: 10.3390/ijms21031069.
- Related Content
Scholarly Community Encyclopedia
Roles of Copper in Cancer
Contributors
The following have contributed to this page
